Enabling and advancing mRNA-LNP medicines from concept to clinic

Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Enabling and advancing mRNA-LNP medicines from concept to clinic

Nucleic acids (e.g., siRNA, mRNA, and saRNA) can be designed and formulated to silence, express, and edit specific genes providing a flexible and powerful approach to preventing and treating diseases. The recent commercialization and widespread distribution of COVID-19 mRNA vaccines has exemplified the massive potential to rapidly develop and scale-up new genomic medicines to protect from emerging viral threats and treat a wide range of serious diseases with unmet medical needs.

This webinar will discuss key insights and experiences that leverage modular microfluidic platform technologies and analytics to enable rapid development, testing, and scale-up of mRNA-LNP vaccines and therapeutics:

Examples from our internal R&D work to demonstrate the versatility of the genetic medicine toolbox for the rapid development of RNA-LNP Vaccines
Key considerations during development of mRNA-LNP medicines and how a comprehensive understanding of Critical Quality Attributes (CQAs) and Key process parameters are critical in developing mRNA-LNP that meet the target product profile
Challenges associated with mRNA-LNP analytical development and impact on biological activity
How Precision NanoSystems employs a panel of over 25 specific assays to de-risk LNP development programs and expedite the path to the clinic